UBS Group’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

UBS Group’s Portfolio DBTX Stock Details DBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,735	Closed	-$6.68K	–	10239
2023 Q2	$6.68K	Buy	1,735 +1,689	+3,672%	+$6.2K	﹤0.01%	7344
2023 Q1	$139	Buy	+46	New	+$159	﹤0.01%	9190
2022 Q3	–	Sell	-1,504	Closed	-$6K	–	11320
2022 Q2	$6K	Buy	+1,504	New	+$3.55K	﹤0.01%	8774
2022 Q1	–	Sell	-95	Closed	–	–	11225
2021 Q4	$0	Buy	+95	New	+$654	﹤0.01%	10977
2021 Q3	–	Sell	-514	Closed	-$4K	–	10335
2021 Q2	$4K	Sell	514 -2,501	-83%	-$22.1K	﹤0.01%	8727
2021 Q1	$34K	Buy	+3,015	New	+$47.3K	﹤0.01%	6911

Other funds holding DBTX

ACA

Atlas Capital Advisors Jackson, Wyoming $875M AUM

UBS Group's DBTX Position: Q3 2023 in Review

UBS Group sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q3 2023, closing a stake of 1,735 shares — an estimated $6.68K sold.

UBS Group first reported a position in DBTX in Q1 2021 and held it in 6 quarters. The position peaked at $34K in Q1 2021. 1 fund tracked by Wall St. Rank holds DBTX as of Q3 2023.

UBS Group reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
UBS Group sold 1,735 Decibel Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $6.68K.
UBS Group first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2021 and held it in 6 quarters.
UBS Group's Decibel Therapeutics, Inc. Common Stock position peaked at $34K in Q1 2021.
1 fund tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q3 2023.

Based on UBS Group's 13F filing for Q3 2023, filed 9 Nov 2023.